Neurovalens receives European CE mark and UK MHRA approval for non-invasive neuromodulation device
Summary
Neurovalens received both European CE mark and UK MHRA approval for their non-invasive neuromodulation device in March 2026, as reported in MassDevice and noted in Neurotech Notables #51. Neurovalens's Modius device uses galvanic vestibular stimulation (GVS) behind the ear to modulate hypothalamic activity — the brain's master metabolic and sleep regulator — for improvements in sleep quality and metabolic health. The simultaneous UK and EU approvals clear the way for commercial launch across the UK's 68 million and EU's 450 million consumer markets, positioning Neurovalens as a commercially available non-prescription brain stimulation device for sleep and metabolism.
Why it matters
Neurovalens achieving both CE mark and UK MHRA approval simultaneously — rather than sequentially — reflects strong regulatory preparation and a compelling clinical evidence package for hypothalamic neuromodulation. For non-invasive brain stimulation companies navigating post-Brexit UK-EU regulatory divergence, dual simultaneous approval is the commercial gold standard. The metabolic and sleep indication creates a consumer wellness product with a genuine neurostimulation mechanism distinct from the wellness wearable category.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial